<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2393-6797</journal-id>
<journal-title><![CDATA[Revista Uruguaya de Medicina Interna ]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Urug. Med. Int.]]></abbrev-journal-title>
<issn>2393-6797</issn>
<publisher>
<publisher-name><![CDATA[Sociedad de Medicina Interna del Uruguay]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2393-67972023000300070</article-id>
<article-id pub-id-type="doi">10.26445/08.03.7</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Síndrome de Guillain-Barré recurrente asociado a vacuna anti-COVID-19. Informe de caso]]></article-title>
<article-title xml:lang="en"><![CDATA[Recurrent Guillain-Barré syndrome associated with anti-COVID-19 vaccine. Case report]]></article-title>
<article-title xml:lang="pt"><![CDATA[Síndrome de Guillain-Barré recorrente associada à vacina anti-COVID-19. Relato de caso]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lastra Jauregui]]></surname>
<given-names><![CDATA[Abel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Suarez Lacabe]]></surname>
<given-names><![CDATA[Amanda]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Ciencias Médicas de La Habana Facultad Manuel Fajardo ]]></institution>
<addr-line><![CDATA[Cuba ]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2023</year>
</pub-date>
<volume>8</volume>
<numero>3</numero>
<fpage>70</fpage>
<lpage>76</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_arttext&amp;pid=S2393-67972023000300070&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_abstract&amp;pid=S2393-67972023000300070&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_pdf&amp;pid=S2393-67972023000300070&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen: El Síndrome de Guillain-Barré constituye la causa más frecuente de parálisis flácida aguda en el mundo. Su diagnóstico es clínico y debe ser respaldado por estudios del líquido cefalorraquídeo y de conducción nerviosa. Se produce como consecuencia de una respuesta inmune cruzada ante antígenos de diferentes patógenos, y se ha asociado también a inmunizaciones previas. Existe escasa literatura sobre su recurrencia asociado a la vacunación anti-COVID-19 en el mundo, y hasta donde los autores tienen conocimiento, este es el único informe asociado a la vacuna Abdala (CIGB-66). Se presenta el caso de un paciente masculino de 55 años de edad que refirió pérdida aguda de la fuerza muscular, el cual presentó complicaciones durante su estancia en la Terapia Intensiva, asociadas a la ventilación mecánica. La dificultad en realizar un diagnóstico rápido y certero, especialmente en países subdesarrollados, donde los estudios especializados no se encuentran siempre disponibles y debe hacerse un diagnóstico eminentemente clínico, motivó a los autores a presentar este caso atípico.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract: Guillain-Barré Syndrome is the most frequent cause of acute flaccid paralysis in the world. Its diagnosis is clinical and must be supported by studies of the cerebrospinal fluid and nerve conduction. It is produced as a consequence of a crossed immune response to antigens from different pathogens, and it has also been associated with previous immunizations. There is little literature on its recurrence associated with anti-COVID-19 vaccination in the world, and as far as the authors are aware, this is the only report associated with the Abdala vaccine (CIGB-66). We present the case of a 55-year-old male patient who reported acute loss of muscle strength, who presented complications during his stay in the Intensive Care Unit, associated with mechanical ventilation. The fact that it is so difficult to give a quick and accurate diagnosis, especially in underdeveloped countries, where specialized studies are not always available and an eminently clinical diagnosis must be made motivated the authors to present this atypical case.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo: A Síndrome de Guillain-Barré é a causa mais frequente de paralisia flácida aguda no mundo. Seu diagnóstico é clínico e deve ser apoiado por estudos do líquido cefalorraquidiano e da condução nervosa. É produzida como consequência de uma resposta imune cruzada a antígenos de diferentes patógenos, e também tem sido associada a imunizações anteriores. Há pouca literatura sobre sua recorrência associada à vacinação anti-COVID-19 no mundo e, até onde os autores sabem, este é o único relato associado à vacina Abdala (CIGB-66). Apresentamos o caso de um paciente do sexo masculino, 55 anos, que relatou perda aguda de força muscular, que apresentou complicações durante sua internação na Unidade de Terapia Intensiva, associada à ventilação mecânica. A dificuldade de um diagnóstico rápido e preciso, principalmente em países subdesenvolvidos, onde nem sempre há estudos especializados e deve ser feito um diagnóstico eminentemente clínico, motivou os autores a apresentarem este caso atípico.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Síndrome de Guillain-Barré]]></kwd>
<kwd lng="es"><![CDATA[recurrencia]]></kwd>
<kwd lng="es"><![CDATA[vacunación]]></kwd>
<kwd lng="es"><![CDATA[Abdala]]></kwd>
<kwd lng="en"><![CDATA[Guillain-Barré syndrome]]></kwd>
<kwd lng="en"><![CDATA[recurrence]]></kwd>
<kwd lng="en"><![CDATA[vaccination]]></kwd>
<kwd lng="en"><![CDATA[Abdala]]></kwd>
<kwd lng="pt"><![CDATA[síndrome de Guillain-Barré]]></kwd>
<kwd lng="pt"><![CDATA[recidiva]]></kwd>
<kwd lng="pt"><![CDATA[vacinação]]></kwd>
<kwd lng="pt"><![CDATA[Abdala]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vera-Carrasco]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Síndrome de Guillain Barré]]></article-title>
<source><![CDATA[Cuad Hosp Clín]]></source>
<year>2019</year>
<volume>60</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>59-64</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shahrizaila]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Lehmann]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
<name>
<surname><![CDATA[Kuwabara]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guillain-Barré syndrome]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2021</year>
<volume>397</volume>
<numero>10280</numero>
<issue>10280</issue>
<page-range>1214-28</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Dong]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ubogu]]></surname>
<given-names><![CDATA[EE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immunotherapy of Guillain-Barré syndrome]]></article-title>
<source><![CDATA[Hum Vaccin Immunother]]></source>
<year>2018</year>
<volume>14</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>2568-79</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sejvar]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Baughman]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Wise]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Morgan]]></surname>
<given-names><![CDATA[OW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Population incidence of Guillain-Barré syndrome a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Neuroepidemiology]]></source>
<year>2011</year>
<volume>36</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>123-33</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López-Hernández]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez-Valdez]]></surname>
<given-names><![CDATA[EY]]></given-names>
</name>
<name>
<surname><![CDATA[León-Manríquez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Bazán-Rodríguez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Galnares Olalde]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Jorge-de Saráchaga]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guillain-Barre syndrome during COVID-19 pandemic experience from a referral healthcare center in Mexico]]></article-title>
<source><![CDATA[Rev Neurol]]></source>
<year>2021</year>
<volume>73</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>315-20</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leonhard]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Tan]]></surname>
<given-names><![CDATA[CY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antecedent infections in Guillain-Barré syndrome in endemic areas of arbovirus transmission A multinational case-control study]]></article-title>
<collab>van der Eijk AA.Reisin RR.Franken SC.Huizinga R</collab>
<source><![CDATA[J Peripher Nerv Syst]]></source>
<year>2021</year>
<volume>26</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>449-60</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Caress]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Castoro]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Simmons]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Scelsa]]></surname>
<given-names><![CDATA[SN]]></given-names>
</name>
<name>
<surname><![CDATA[Lewis]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Ahlawat]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[COVID-19-associated Guillain-Barré syndrome The early pandemic experience]]></article-title>
<source><![CDATA[Muscle Nerve]]></source>
<year>2020</year>
<volume>62</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>485-91</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dy]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Leshner]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Crawford]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An unusual case of recurrent guillain-barre syndrome of a different subtype five years after initial diagnosis]]></article-title>
<source><![CDATA[Case Rep Neurol Med]]></source>
<year>2013</year>
<volume>2013</volume>
<page-range>356157</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kuitwaard]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[van Koningsveld]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ruts]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Jacobs]]></surname>
<given-names><![CDATA[BC]]></given-names>
</name>
<name>
<surname><![CDATA[van Doorn]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recurrent Guillain-Barré syndrome]]></article-title>
<source><![CDATA[J Neurol Neurosurg Psychiatry]]></source>
<year>2009</year>
<volume>80</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>56-9</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Domínguez]]></surname>
<given-names><![CDATA[LG]]></given-names>
</name>
<name>
<surname><![CDATA[Alcocer]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Domínguez]]></surname>
<given-names><![CDATA[LG]]></given-names>
</name>
<name>
<surname><![CDATA[Arellano]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Síndrome de Guillain-Barré recurrente asociado con infección por SARS-CoV-2]]></article-title>
<source><![CDATA[Acta Médica Grupo Ángeles]]></source>
<year>2021</year>
<volume>19</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>554-7</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vargas-Cañas]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
<name>
<surname><![CDATA[Chiquete]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Ruano-Calderón]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[León Manríquez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Salmerón-Mercado]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Plascencia-Álvarez]]></surname>
<given-names><![CDATA[NI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recomendaciones sobre el diagnóstico y tratamiento de la Polineuropatía desmielinizante inflamatoria crónica]]></article-title>
<source><![CDATA[Rev Mex Neuro]]></source>
<year>2017</year>
<volume>18</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>2-19</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leonhard Sonja]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Mandarakas]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[De Assis Aquino Gondim]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Kathleen]]></surname>
<given-names><![CDATA[Bateman]]></given-names>
</name>
<name>
<surname><![CDATA[Brito Ferreira]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Cornblath]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guía basada en la evidencia. Diagnóstico y manejo del síndrome de Guillain-Barré en diez pasos.]]></article-title>
<source><![CDATA[Medicina (Buenos Aires)]]></source>
<year>2021</year>
<volume>81</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>817-36</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alva-Díaz]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Mori]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Pacheco-Barrios]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Velásquez-Rimachi]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Rivera-Torrejona]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Huerta-Rosario]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guía de práctica clínica para el diagnóstico y tratamiento del paciente con síndrome de Guillain-Barré]]></article-title>
<source><![CDATA[Neurol Arg]]></source>
<year>2020</year>
<volume>12</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>36-48</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vega-Fernández]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Suclupe-Campos]]></surname>
<given-names><![CDATA[DO]]></given-names>
</name>
<name>
<surname><![CDATA[Coico-Vega]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Aguilar-Gamboa]]></surname>
<given-names><![CDATA[FR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Etiología viral en el síndrome de Guillain-Barré: Buscando una respuesta a lo idiopático]]></article-title>
<source><![CDATA[Rev Fac Med Humana]]></source>
<year>2022</year>
<volume>22</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>584-96</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Finsterer]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Scorza]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
<name>
<surname><![CDATA[Scorza]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Post SARS-CoV-2 vaccination Guillain-Barre syndrome in 19 patients]]></article-title>
<source><![CDATA[Clinics (Sao Paulo)]]></source>
<year>2021</year>
<volume>76</volume>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Min]]></surname>
<given-names><![CDATA[YG]]></given-names>
</name>
<name>
<surname><![CDATA[Hong]]></surname>
<given-names><![CDATA[YH]]></given-names>
</name>
<name>
<surname><![CDATA[Song]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Associations of Guillain-Barré syndrome with coronavirus disease 2019 vaccination Disproportionality analysis using the World Health Organization pharmacovigilance database]]></article-title>
<source><![CDATA[J Peripher Nerv Syst]]></source>
<year>2022</year>
<volume>27</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>206-14</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wan]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kapadia]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Hahn]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Case Series of Guillain-Barré Syndrome After the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) Vaccine]]></article-title>
<source><![CDATA[Neurol Clin Pract]]></source>
<year>2022</year>
<volume>12</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>149-53</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Keh]]></surname>
<given-names><![CDATA[RYS]]></given-names>
</name>
<name>
<surname><![CDATA[Scanlon]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Datta-Nemdharry]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Donegan]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Cavanagh]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Foster]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Skelland]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Palmer]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Machado]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Keddie]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Carr]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Lunn]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[COVID-19 vaccination and Guillain-Barré syndrome analyses using the National Immunoglobulin Database]]></article-title>
<collab>BPNS/ABN COVID-19 Vaccine GBS Study Group</collab>
<source><![CDATA[Brain]]></source>
<year>2023</year>
<volume>146</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>739-48</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<collab>Shapiro Ben David S.Potasman I.Rahamim-Cohen D</collab>
<article-title xml:lang=""><![CDATA[Rate of Recurrent Guillain-Barré Syndrome After mRNA COVID-19 Vaccine BNT162b2]]></article-title>
<source><![CDATA[JAMA Neurol]]></source>
<year>2021</year>
<volume>78</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1409-11</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hernández-Bernal]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Ricardo-Cobas]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Martin-Bauta]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Navarro-Rodríguez]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Piñera-Martínez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Quintana-Guerra]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine A randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study)]]></article-title>
<source><![CDATA[EClinicalMedicine]]></source>
<year>2022</year>
<volume>46</volume>
<page-range>101383</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ubogu]]></surname>
<given-names><![CDATA[EE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inflammatory neuropathies pathology, molecular markers and targets for specific therapeutic intervention]]></article-title>
<source><![CDATA[Acta Neuropathol]]></source>
<year>2015</year>
<volume>130</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>445-68</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cutillo]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Saariaho]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
<name>
<surname><![CDATA[Meri]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Physiology of gangliosides and the role of antiganglioside antibodies in human diseases]]></article-title>
<source><![CDATA[Cell Mol Immunol]]></source>
<year>2020</year>
<volume>17</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>313-22</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chiang]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ubogu]]></surname>
<given-names><![CDATA[EE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The role of chemokines in Guillain-Barré syndrome]]></article-title>
<source><![CDATA[Muscle Nerve]]></source>
<year>2013</year>
<volume>48</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>320-30</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oaklander]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Lunn]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Hughes]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[van Schaik]]></surname>
<given-names><![CDATA[IN]]></given-names>
</name>
<name>
<surname><![CDATA[Frost]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Chalk]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) an overview of systematic reviews]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2017</year>
<volume>1</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>CD010369</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ruts]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Drenthen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Jacobs]]></surname>
<given-names><![CDATA[BC]]></given-names>
</name>
<name>
<surname><![CDATA[van Doorn]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome a prospective study]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>2010</year>
<volume>74</volume>
<numero>21</numero>
<issue>21</issue>
<page-range>1680-6</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Galeas Oliva]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ramos]]></surname>
<given-names><![CDATA[FC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Síndrome de Guillain-Barré recurrente: reporte de caso]]></article-title>
<source><![CDATA[Acta pediátr hondu]]></source>
<year>2017</year>
<volume>8</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>791-5</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
